UBS Group
ATHE

UBS Group’s Alterity Therapeutics ATHE Stock Holding History

UBS Group’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-63
Closed -$6K – 8786
2014
Q4 		$6K Buy
+63
New +$6.81K ﹤0.01% 8800

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

UBS Group's ATHE Position: Q2 2026 in Review

UBS Group opened a new position in Alterity Therapeutics (ATHE) in Q2 2026: 5 shares worth $27. The stake represents ﹤0.01% of the portfolio and ranks #10244 among its holdings. This is a return to the name: UBS Group previously reported a position in ATHE as recently as Q1 2025.

UBS Group first reported a position in ATHE in Q4 2014 and has held it in 34 quarters since. The position peaked at $63K in Q2 2020. 22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • UBS Group held 5 shares of Alterity Therapeutics worth $27 as of Q2 2026.
  • Alterity Therapeutics was a new UBS Group position in Q2 2026.
  • Alterity Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10244 holding.
  • UBS Group first reported a position in Alterity Therapeutics in Q4 2014 and has held it in 34 quarters since.
  • UBS Group's Alterity Therapeutics position peaked at $63K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.